Obesity Modifies the Relationship Between Raltegravir and Dolutegravir Hair Concentrations and Body Weight Gain in Women Living with HIV

Integrase strand-transfer inhibitors (INSTIs) are associated with weight gain in women living with HIV (WLH). Relationships between drug exposure, baseline obesity, and INSTI-associated weight gain remain unclear. Data from 2006 to 2016 were analyzed from virally suppressed WLH enrolled in the Women...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	AIDS research and human retroviruses 2023-12, Vol.39 (12), p.644-651
Hauptverfasser:	Lahiri, Cecile D, Mehta, C Christina, Sykes, Craig, Weiser, Sheri D, Palella, Frank, Lake, Jordan E, Mellors, John W, Gustafson, Deborah, French, Audrey L, Adimora, Adaora A, Konkle-Parker, Deborah, Sharma, Anjali, Bolivar, Hector, Kassaye, Seble G, Rubin, Leah H, Alvarez, Jessica A, Golub, Elizabeth T, Ofotokun, Igho, Sheth, Anandi N
Format:	Artikel
Sprache:	eng
Schlagworte:	Female Heterocyclic Compounds, 3-Ring - adverse effects HIV Infections - drug therapy HIV Integrase - genetics HIV Integrase Inhibitors - adverse effects HIV-1 - genetics Humans Middle Aged Obesity - drug therapy Outcomes Research Oxazines - therapeutic use Raltegravir Potassium - pharmacology Raltegravir Potassium - therapeutic use Weight Gain
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!